AbbVie, a global research biopharmaceutical company, and R-Pharm Group announced the completion of technology transfer for manufacturing Kaletra® (lopinavir + ritonavir) intended for treatment of HIV/AIDS infection in adult patients.
Full-cycle manufacturing of Kaletra® formulation will be carried out in the pharmaceutical facility of R-Pharm located in Yaroslavl from a substance produced by AbbVie.
Currently, there are 943,999 HIV patients registered in Russia, including 346,000 patients on continuous antiretroviral therapy (ART). The therapy coverage keeps growing in line with the government and public objectives to combat HIV/AIDS epidemic in Russia. Compared to 2012, the number of patients receiving ART increased by 2.76 times.
Anthony Wong, Regional Vice President – Russia, Ukraine & CIS at AbbVie:
“In AbbVie, we strive to make a significant impact on the lives of patients. Antiretroviral therapy allows patients to live a normal, healthy life and keep their infections under control which, in turn, helps to contain the spread of epidemic. Localizing full-cycle manufacturing of the drug is a step forward in increasing the availability of HIV treatment for patients in Russia.”
Vasily Ignatiev, General Director of R-Pharm Group:
“The completion of technology transfer and full-cycle manufacturing of the drug for HIV/AIDS treatment is an important stage in the implementation of Pharma-2020 strategy. We expect that our cooperation with AbbVie will lead to more effective fight against diseases caused by human immunodeficiency virus.”